These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 7650677)

  • 1. A check on rational drug design: crystal structure of a complex of human immunodeficiency virus type 1 protease with a novel gamma-turn mimetic inhibitor.
    Hoog SS; Zhao B; Winborne E; Fisher S; Green DW; DesJarlais RL; Newlander KA; Callahan JF; Moore ML; Huffman WF
    J Med Chem; 1995 Aug; 38(17):3246-52. PubMed ID: 7650677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational design, synthesis, and crystallographic analysis of a hydroxyethylene-based HIV-1 protease inhibitor containing a heterocyclic P1'--P2' amide bond isostere.
    Thompson SK; Murthy KH; Zhao B; Winborne E; Green DW; Fisher SM; DesJarlais RL; Tomaszek TA; Meek TD; Gleason JG
    J Med Chem; 1994 Sep; 37(19):3100-7. PubMed ID: 7932533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal structure of a complex of HIV-1 protease with a dihydroxyethylene-containing inhibitor: comparisons with molecular modeling.
    Thanki N; Rao JK; Foundling SI; Howe WJ; Moon JB; Hui JO; Tomasselli AG; Heinrikson RL; Thaisrivongs S; Wlodawer A
    Protein Sci; 1992 Aug; 1(8):1061-72. PubMed ID: 1304383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of human immunodeficiency virus-1 protease by a C2-symmetric phosphinate. Synthesis and crystallographic analysis.
    Abdel-Meguid SS; Zhao B; Murthy KH; Winborne E; Choi JK; DesJarlais RL; Minnich MD; Culp JS; Debouck C; Tomaszek TA
    Biochemistry; 1993 Aug; 32(31):7972-80. PubMed ID: 8347601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor.
    Bäckbro K; Löwgren S; Osterlund K; Atepo J; Unge T; Hultén J; Bonham NM; Schaal W; Karlén A; Hallberg A
    J Med Chem; 1997 Mar; 40(6):898-902. PubMed ID: 9083478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate -- interactions with frequently occurring glutamic acid residue at P2' position of substrates.
    Weber IT; Wu J; Adomat J; Harrison RW; Kimmel AR; Wondrak EM; Louis JM
    Eur J Biochem; 1997 Oct; 249(2):523-30. PubMed ID: 9370363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure of HOE/BAY 793 complexed to human immunodeficiency virus (HIV-1) protease in two different crystal forms--structure/function relationship and influence of crystal packing.
    Lange-Savage G; Berchtold H; Liesum A; Budt KH; Peyman A; Knolle J; Sedlacek J; Fabry M; Hilgenfeld R
    Eur J Biochem; 1997 Sep; 248(2):313-22. PubMed ID: 9346283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The crystal structures at 2.2-A resolution of hydroxyethylene-based inhibitors bound to human immunodeficiency virus type 1 protease show that the inhibitors are present in two distinct orientations.
    Murthy KH; Winborne EL; Minnich MD; Culp JS; Debouck C
    J Biol Chem; 1992 Nov; 267(32):22770-8. PubMed ID: 1429626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-dimensional structure of a simian immunodeficiency virus protease/inhibitor complex. Implications for the design of human immunodeficiency virus type 1 and 2 protease inhibitors.
    Zhao B; Winborne E; Minnich MD; Culp JS; Debouck C; Abdel-Meguid SS
    Biochemistry; 1993 Dec; 32(48):13054-60. PubMed ID: 8241159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance.
    Hong L; Zhang XC; Hartsuck JA; Tang J
    Protein Sci; 2000 Oct; 9(10):1898-904. PubMed ID: 11106162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation and structure-activity relationship of novel P1/P1'-substituted cyclic urea-based human immunodeficiency virus type-1 protease inhibitors.
    Nugiel DA; Jacobs K; Kaltenbach RF; Worley T; Patel M; Meyer DT; Jadhav PK; De Lucca GV; Smyser TE; Klabe RM; Bacheler LT; Rayner MM; Seitz SP
    J Med Chem; 1996 May; 39(11):2156-69. PubMed ID: 8667359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease: structure-activity analysis using enzyme kinetics, X-ray crystallography, and infected T-cell assays.
    Dreyer GB; Lambert DM; Meek TD; Carr TJ; Tomaszek TA; Fernandez AV; Bartus H; Cacciavillani E; Hassell AM; Minnich M
    Biochemistry; 1992 Jul; 31(29):6646-59. PubMed ID: 1637805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel constrained reduced-amide inhibitor of HIV-1 protease derived from the sequential incorporation of gamma-turn mimetics into a model substrate.
    Newlander KA; Callahan JF; Moore ML; Tomaszek TA; Huffman WF
    J Med Chem; 1993 Aug; 36(16):2321-31. PubMed ID: 8360876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular recognition of cyclic urea HIV-1 protease inhibitors.
    Ala PJ; DeLoskey RJ; Huston EE; Jadhav PK; Lam PY; Eyermann CJ; Hodge CN; Schadt MC; Lewandowski FA; Weber PC; McCabe DD; Duke JL; Chang CH
    J Biol Chem; 1998 May; 273(20):12325-31. PubMed ID: 9575185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Energy calculations and analysis of HIV-1 protease-inhibitor crystal structures.
    Gustchina A; Sansom C; Prevost M; Richelle J; Wodak SY; Wlodawer A; Weber IT
    Protein Eng; 1994 Mar; 7(3):309-17. PubMed ID: 8177879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ligand modifications to reduce the relative resistance of multi-drug resistant HIV-1 protease.
    Dewdney TG; Wang Y; Liu Z; Sharma SK; Reiter SJ; Brunzelle JS; Kovari IA; Woster PM; Kovari LC
    Bioorg Med Chem; 2013 Dec; 21(23):7430-4. PubMed ID: 24128815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of novel HIV-1 protease inhibitors incorporating isophthalamide-derived P2-P3 ligands: Synthesis, biological evaluation and X-ray structural studies of inhibitor-HIV-1 protease complex.
    Ghosh AK; Brindisi M; Nyalapatla PR; Takayama J; Ella-Menye JR; Yashchuk S; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
    Bioorg Med Chem; 2017 Oct; 25(19):5114-5127. PubMed ID: 28434781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains.
    Tie Y; Boross PI; Wang YF; Gaddis L; Hussain AK; Leshchenko S; Ghosh AK; Louis JM; Harrison RW; Weber IT
    J Mol Biol; 2004 Apr; 338(2):341-52. PubMed ID: 15066436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of HIV-1 protease inhibitors. Novel tetrahydrofuran P2/P2'-groups interacting with Asp29/30 of the HIV-1 protease. Determination of binding from X-ray crystal structure of inhibitor protease complex.
    Oscarsson K; Lahmann M; Lindberg J; Kangasmetsä J; Unge T; Oscarson S; Hallberg A; Samuelsson B
    Bioorg Med Chem; 2003 Mar; 11(6):1107-15. PubMed ID: 12614898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine.
    Baldwin ET; Bhat TN; Gulnik S; Liu B; Topol IA; Kiso Y; Mimoto T; Mitsuya H; Erickson JW
    Structure; 1995 Jun; 3(6):581-90. PubMed ID: 8590019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.